Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-[18F]fluoro-para-hydroxyphenethylguanidine
- Development stage
- Phase 1
- Lead developer
- University of Michigan Rogel Cancer Center
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
3-[18F]fluoro-para-hydroxyphenethylguanidine is a radiopharmaceutical positron emission tomography (PET) imaging agent designed as a structural analog of norepinephrine. It acts as a substrate for the norepinephrine transporter (NET) and vesicular monoamine transporters (VMAT1, VMAT2), enabling visualization of sympathetic nerve terminals and neuroendocrine tumors that express these transporters. The compound is used primarily for functional imaging and staging of malignant paraganglioma, pheochromocytoma, and other neuroendocrine tumors, as well as quantification of regional cardiac sympathetic nerve density in heart failure patients. Its mechanism involves selective uptake by NET-expressing tissues, providing high lesion affinity with favorable imaging properties compared to other tracers such as [123I]mIBG or [68Ga]DOTATATE[1][2][5][6][7].
- Other names
- fluorine F 18 3F-PHPG
02
Targets
NET (Norepinephrine Transporter)VMAT2 (Vesicular monoamine transporter 2)VMAT1 (Vesicular monoamine transporter type 1)
Beyond the preview
Go deeper on 3-[18F]fluoro-para-hydroxyphenethylguanidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3-[18F]fluoro-para-hydroxyphenethylguanidine.